About
Andrew D. Dickinson is Gilead's Chief Financial Officer, overseeing the company's global finance, corporate development, information technology, operations and strategy organizations.
He joined Gilead in 2016 as head of the company's corporate development and strategy group, where he drove Gilead's licensing, partnership and acquisition transactions and guided investments into new areas. Before Gilead he was the global Co-Head of Healthcare Investment Banking at Lazard, and earlier served as General Counsel and Vice President of Corporate Development at Myogen Inc., which Gilead acquired in 2006.
Roles
Gilead Sciences, Inc.
Chief Financial Officer · Current role
2016–present
Gilead Sciences, Inc.
Head of Corporate Development and Strategy · Drove all of Gilead's licensing, partnership and acquisition transactions and guided investments into new areas.
—
Lazard
Global Co-Head of Healthcare Investment Banking
—
Myogen, Inc.
General Counsel and Vice President of Corporate Development · Myogen was acquired by Gilead in 2006.
—
Gilead Sciences, Inc.
Executive Vice President, Corporate Development and Strategy · Role held prior to appointment as CFO effective November 1, 2019.
—
External Roles
Sutter Health
Member, Board of Directors
—
Galapagos NV
Former Member, Board of Directors
—
Fosun Pharma / Kite joint venture (China)
Former Member, Board of Directors
—
Fixed Compensation
FY 2025Salary
$1,116,654
ComponentAnnual base salary (FY2025)
All other compensation
$70,979
Perquisites and other personal benefits$48,497
Contributions to 401(k) plan$15,000
Insurance premiums$7,482
Total compensation
$8,765,616
Performance Compensation
Data from FY 2025Cash incentive
Annual cash incentive
$1,956,266
FormNon-Equity Incentive Plan Compensation
Target Opportunity
—
Target incentive opportunity$1,123,000 (100% of salary)
Corporate performance factor134%
Individual performance factor130%
Maximum payout200% of target
Stock awards
Stock awards
$4,321,741
FormPerformance shares (50% of target LTI) and restricted stock units (25% of target LTI)
Performance shares metricRelative Total Shareholder Return (TSR) and multi-year EPS growth, earned over three years
RSU vestingOver four years
Option awards
$1,299,976
FormStock options
Weight of target LTI25%
VestingOver four years, beginning one year after grant with quarterly vesting thereafter
Also at Gilead Sciences, Inc.
See how Top Bucket AI works for your firm
Request DemoTop Bucket AI Research
Stay ahead of private markets
Research and market intelligence for private-markets professionals.
✓
You're subscribed.
Thanks for signing up.